The Effect of Monocyte Values Accompanied by Lymphopenia on the Prognosis of Patients Diagnosed With COVID-19

Completed

• Conditions: COVID 19; Lymphopenia Due to COVID-19; Monocyte

• Registration Number: NCT06968156
• Lead Sponsor: Kanuni Sultan Suleyman Training and Research Hospital

Brief Summary

Recent studies have shown that lymphopenia with cytokine storm syndrome is frequently found in COVID-19 patients. These features may suggest that the modified immune system plays a key role in determining disease progression. Lymphopenia or lymphocytopenia is a condition in which the number of lymphocytes in the blood is low. Although T cells can be increased at the onset of COVID-19, these patients tend to have low lymphocyte counts, which is associated with increased COVID-19 severity. Thus, individuals who died of COVID-19 have been shown to have significantly lower lymphocyte levels than survivors. There is evidence that myeloid cells play a role in the pathophysiology of coronavirus infection, either directly as virus targets or indirectly as effectors of cytokine release syndrome. Monocytes are innate hematopoietic cells that maintain vascular homeostasis and provide early responses to pathogens during acute infections. The role of monocytes and macrophages in the resolution of inflammation has also been emphasized as an important component of the response to SARS-CoV-2. Accordingly, it was investigated whether the change observed in blood monocyte levels was an effective parameter in the prognosis process in Covid-19 cases with lymphopenia, considering that monocyte levels could be useful as a guide in the course of the disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-01
• Primary Completion: 2020-09-30
• Study Completion: 2020-09-30
• Status Verified: 2025-05
• Study First Submitted: 2025-05-01
• Study First Submitted QC: 2025-05-09
• Last Update Submitted: 2025-05-12
• Study First Posted: 2025-05-13
• Last Update Posted: 2025-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients over the age of 18
• Male and female of both genders
• Admitted to the intensive care unit
• Diagnosed with Covid-19 with lymphopenia
• Patients with confirmed COVID-19 diagnosis in polymerase chain reaction (PCR) tests performed on nasopharyngeal swab samples

Exclusion Criteria

• Those with a negative PCR test
• Aged 18 and under

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prognostic course, rate of mortality	through study completion, an average of 5 month	The parameters examined will be survival and exitus status, age, weight in kilograms, height in centimeters, weight and height will be combined to report BMI in kg/m\^2, gender, presence of additional disease, ferritin, D-dimer, C-reactive protein, lactate dehydrogenase, procalcitonin, fibrinogen, hemoglobin, leukocyte, platelet, neutrophil, eosinophil, basophil, monocyte, lymphocyte levels measured during admission to the intensive care unit. Lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio will be obtained from the detected data. The existing O2 requirement at admission to the intensive care unit was recorded retrospectively as fractional inspired oxygen (FiO2) value, the source of oxygen support and the existing Covid-19 treatment. The hemodialysis, vasopressor and intubation requirement that developed during the hospitalization and the exitus status during hospitalization were evaluated.

Trial Locations

Locations (1)

Kanuni Sultan Suleyman Training and Research Hospital; 🇹🇷 İstanbul, Turkey